LBL-007

Overview

LBL-007 is an investigational anti-LAG-3 monoclonal antibody targeting LAG3, an inhibitory receptor on exhausted T cells. It is evaluated in combination with toripalimab in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• LBL-007 + toripalimab in R/M NPC (NCT05102006, n=30): ORR 33.3% in ICI-naïve (n=12) and 11.8% in ICI-refractory (n=17); median PFS 10.8 months; median DOR 15 months PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.